Press release content from Business Wire. The AP news staff was not involved in its creation.

Anorexia Nervosa Drug Pipeline Landscape Report 2022: Therapeutic Assessment of Key Products Such as Psilocybin and Ibogaine -

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
December 20, 2022 GMT

DUBLIN--(BUSINESS WIRE)--Dec 20, 2022--

The “Anorexia Nervosa - Pipeline Insight, 2022” clinical trials has been added to’s offering.

This “Anorexia Nervosa - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anorexia Nervosa pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

“Anorexia Nervosa - Pipeline Insight, 2022” report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anorexia Nervosa pipeline landscape is provided which includes the disease overview and Anorexia Nervosa treatment guidelines.

The assessment part of the report embraces, in depth Anorexia Nervosa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anorexia Nervosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


Anorexia Nervosa Emerging Drugs Chapters

This segment of the Anorexia Nervosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anorexia Nervosa Emerging Drugs

Psilocybin: COMPASS Pathways

Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. The company is conducting a phase II clinical trial investigating the efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa.


Ibogaine: Biomind Labs

Ibogaine is being developed by Biomind Labs for the treatment of anorexia nervosa, substance related disorders and neurological disorders.

Anorexia Nervosa: Therapeutic Assessment

This segment of the report provides insights about the different Anorexia Nervosa drugs segregated based on following parameters that define the scope of the report.

Major Players in Anorexia Nervosa

There are approx. 3+ key companies which are developing the therapies for Anorexia Nervosa. The companies which have their Anorexia Nervosa drug candidates in the most advanced stage, i.e. phase II include, COMPASS Pathways.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Anorexia Nervosa.
  • In the coming years, the Anorexia Nervosa market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Anorexia Nervosa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Anorexia Nervosa treatment market. Several potential therapies for Anorexia Nervosa are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Anorexia Nervosa market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Anorexia Nervosa) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.




The report covers around 3+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine
  • Product Type


Anorexia Nervosa Report Insights

  • Anorexia Nervosa Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Anorexia Nervosa Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Players

  • COMPASS Pathways
  • Biomind Labs
  • Short Wave Pharma
  • Artelo Biosciences

Key Products

  • Psilocybin
  • Ibogaine

Research programme: psychedelics-based therapeutics

  • ART27.13

For more information about this clinical trials report visit

View source version on


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2022.

PUB: 12/20/2022 10:41 AM/DISC: 12/20/2022 10:41 AM